Clinical Trials
11 trialsNCT07509034 2026-05-27
Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease
National Institutes of Health Clinical Center (CC)
Phase 1 Not yet recruiting
NCT07246304 2025-11-24
TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC
TCRCure Biopharma Ltd.
Phase EARLY_PHASE1 Recruiting
NCT03841110 2023-05-01
FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
Fate Therapeutics
Phase 1 Completed
NCT04596033 2022-07-15
TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy
Genocea Biosciences, Inc.
Phase 1 Terminated
NCT02566993 2021-10-28
ATLANTIS
PharmaMar
Phase 3 Completed
NCT00499733 2019-01-18
Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Terminated
NCT00006126 2015-11-13
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
Northwestern University
Phase 1 Withdrawn
NCT00759824 2015-02-12
A Phase II Study of Doxorubicin, Cyclophosphamide and Vindesine With Valproic Acid in Patients With Refractory or Relapsing Small Cell Lung Cancer After Platinum Derivatives and Etoposide
European Lung Cancer Working Party
Phase 2 Completed
NCT00002475 2013-07-10
Cyclophosphamide Plus Vaccine Therapy in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 2 Completed
NCT00083161 2012-09-05
Cisplatin, Etoposide, and Cyclophosphamide in Treating Patients With Extensive-Stage Small Cell Lung Cancer
Gundersen Lutheran Health System
Phase 2 Completed
NCT01212887 2012-02-28
Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer
Cancer Research UK
Phase 1 Terminated